Avizakimab, formerly known as BOS161721, represents a novel therapeutic approach to treating immune-mediated diseases . This antibody medication selectively targets IL-18 , a vital signaling molecule implicated in the pathogenesis of several severe illnesses. Preclinical research have shown Aviza

Rosmantuzumab: A Deep Dive into OMP-131R10 Rosmantuzumab, formerly known through OMP-131R10, constitutes a unique monoclonal immunoglobulin designed to inhibit granulocyte-macrophage colony-stimulating factor. Its mechanism of action involves selectively attaching to GM-CSF, inhibiting